semaglutide hepatic impairment child pugh Is appropriate for a patient with liver fibrosis due to non‑alcoholic fatty liver disease/non‑alcoholic steatohepatitis, who has type 2 diabetes, is overweight/obese, has high cardiovascular risk, and does not have decompensated Focus on Semaglutide 2.4 mg/week
Description
Who Needs Extra Caution

which approach is right for you is determined by your clinician after a full evaluation, and results vary from person to person
It is an investigational drug currently in Phase 3 clinical trials under the TRIUMPH programme

[DOI] [PubMed] [Google Scholar] 137.Lvy P, Kohler M, McNicholas WT, Barb F, McEvoy RD, Somers VK, et al

Those taking multiple medications should inform all prescribers about their weight loss injection to ensure appropriate consideration of potential drug interactions

You can book directly with our Chandler clinic
